{
    "nct_id": "NCT03193918",
    "official_title": "Phase I/Ib Study of Crenolanib With Ramucirumab and Paclitaxel as Second Line Therapy for Advanced Esophagogastric Adenocarcinoma",
    "inclusion_criteria": "* Pathologically confirmed adenocarcinoma of the esophagus, GEJ or stomach.\n* Stage IV disease or locally advanced/unresectable tumors\n* Prior progression on only 1 line of chemotherapy in the advanced/metastatic setting containing a fluoropyrimidine and/or platinum compound\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with a taxane is not permitted in the dose-expansion phase. Patients in the dose escalation component may have received a taxane in the peri-operative setting, provided they developed disease recurrence >6 months after the completion of this therapy\n* Known pre-existing liver disease (e.g. cirrhosis, chronic hepatitis B or C, nonalcoholic steatohepatitis, sclerosing cholangitis)\n* Patients with any clinically apparent ascites or who have undergone a paracentesis within 7 days of enrollment\n* Uncontrolled hypertension (systolic pressure >140 mm Hg or diastolic pressure > 90 mm Hg on repeated measurement) despite optimal medical management\n* Active or clinically significant cardiac disease\n* Patients with arterial thrombotic events, such as cerebrovascular accident or myocardial infarction, within 6 months of enrollment",
    "miscellaneous_criteria": ""
}